Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trial
IntroductionUveal melanoma (UM) is a rare ocular cancer. While germline mutations in genes such as BAP1 and MBD4 account for approximately 20% of familial UM cases, the hereditary factors underlying the remaining cases remain unknown. Epidemiological studies have suggested an increased risk of prost...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1538924/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589850109280256 |
|---|---|
| author | Mélanie Godiveau Mélanie Godiveau Mélanie Godiveau Angeline Ginzac Angeline Ginzac Angeline Ginzac Yannick Bidet Yannick Bidet Flora Ponelle-Chachuat Flora Ponelle-Chachuat Maud Privat Maud Privat Xavier Durando Xavier Durando Xavier Durando Xavier Durando Mathias Cavaillé Mathias Cavaillé Mathis Lepage Mathis Lepage |
| author_facet | Mélanie Godiveau Mélanie Godiveau Mélanie Godiveau Angeline Ginzac Angeline Ginzac Angeline Ginzac Yannick Bidet Yannick Bidet Flora Ponelle-Chachuat Flora Ponelle-Chachuat Maud Privat Maud Privat Xavier Durando Xavier Durando Xavier Durando Xavier Durando Mathias Cavaillé Mathias Cavaillé Mathis Lepage Mathis Lepage |
| author_sort | Mélanie Godiveau |
| collection | DOAJ |
| description | IntroductionUveal melanoma (UM) is a rare ocular cancer. While germline mutations in genes such as BAP1 and MBD4 account for approximately 20% of familial UM cases, the hereditary factors underlying the remaining cases remain unknown. Epidemiological studies have suggested an increased risk of prostate cancer, thyroid cancer, and leukemia among patients with UM, indicating potential unidentified genetic predispositions. This study aims to identify new candidate genes associated with a hereditary predisposition to UM.MethodsThis single-center study, conducted at Centre Jean Perrin, will involve the exome sequencing of 50 patients with UM who do not harbor known pathogenic variants in the BAP1 or MBD4 genes. The primary objective is to identify novel candidate genes associated with hereditary cancer predisposition among UM patients. A several-step-bioinformatic analysis will be conducted to identify the genes of interest. A secondary objective is to explore genes known to be involved in predisposition to other cancers, already described in the occurrence of uveal melanoma, but where an association has not been fully established yet. The study has begun in October 2024, with patient recruitment lasting 12 months. No follow-up period is planned, but the duration of the genetic analyses is estimated at six months, with the final study report expected by October 2026.DiscussionThe identification of novel hereditary predisposition genes for UM could significantly enhance genetic counselling and surveillance strategies for families affected. This study could also contribute to a better understanding of the genetic landscape of UM, potentially leading to more personalized and effective options for its detection.Trial registrationClinicalTrials.gov, identifier NCT06550674, registered in August 2024. Protocol: version 1.0, January 18th, 2024. |
| format | Article |
| id | doaj-art-74a8d526c8eb433a9fa9032adc1c32f3 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-74a8d526c8eb433a9fa9032adc1c32f32025-01-24T07:13:44ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011510.3389/fonc.2025.15389241538924Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trialMélanie Godiveau0Mélanie Godiveau1Mélanie Godiveau2Angeline Ginzac3Angeline Ginzac4Angeline Ginzac5Yannick Bidet6Yannick Bidet7Flora Ponelle-Chachuat8Flora Ponelle-Chachuat9Maud Privat10Maud Privat11Xavier Durando12Xavier Durando13Xavier Durando14Xavier Durando15Mathias Cavaillé16Mathias Cavaillé17Mathis Lepage18Mathis Lepage19Université Clermont Auvergne, Institut National de la santé et de la recherche en innovation (INSERM), Unité mixte de recherche (UMR) 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Center Jean Perrin, Clermont-Ferrand, FranceDivision de Recherche Clinique, Délégation Recherche Clinique and Innovation, Center Jean Perrin, Clermont-Ferrand, FranceCentre d’Investigation Clinique (CIC), UMR501, Clermont-Ferrand, FranceUniversité Clermont Auvergne, Institut National de la santé et de la recherche en innovation (INSERM), Unité mixte de recherche (UMR) 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Center Jean Perrin, Clermont-Ferrand, FranceDivision de Recherche Clinique, Délégation Recherche Clinique and Innovation, Center Jean Perrin, Clermont-Ferrand, FranceCentre d’Investigation Clinique (CIC), UMR501, Clermont-Ferrand, FranceUniversité Clermont Auvergne, Institut National de la santé et de la recherche en innovation (INSERM), Unité mixte de recherche (UMR) 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Center Jean Perrin, Clermont-Ferrand, FranceDépartement d’Oncogénétique, Laboratoire d’Oncologie Moléculaire, Center Jean Perrin, Clermont-Ferrand, FranceUniversité Clermont Auvergne, Institut National de la santé et de la recherche en innovation (INSERM), Unité mixte de recherche (UMR) 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Center Jean Perrin, Clermont-Ferrand, FranceDépartement d’Oncogénétique, Laboratoire d’Oncologie Moléculaire, Center Jean Perrin, Clermont-Ferrand, FranceUniversité Clermont Auvergne, Institut National de la santé et de la recherche en innovation (INSERM), Unité mixte de recherche (UMR) 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Center Jean Perrin, Clermont-Ferrand, FranceDépartement d’Oncogénétique, Laboratoire d’Oncologie Moléculaire, Center Jean Perrin, Clermont-Ferrand, FranceUniversité Clermont Auvergne, Institut National de la santé et de la recherche en innovation (INSERM), Unité mixte de recherche (UMR) 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Center Jean Perrin, Clermont-Ferrand, FranceDivision de Recherche Clinique, Délégation Recherche Clinique and Innovation, Center Jean Perrin, Clermont-Ferrand, FranceCentre d’Investigation Clinique (CIC), UMR501, Clermont-Ferrand, FranceDépartement d’Oncologie Médicale, Center Jean Perrin, Clermont-Ferrand, FranceUniversité Clermont Auvergne, Institut National de la santé et de la recherche en innovation (INSERM), Unité mixte de recherche (UMR) 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Center Jean Perrin, Clermont-Ferrand, FranceDépartement d’Oncogénétique, Laboratoire d’Oncologie Moléculaire, Center Jean Perrin, Clermont-Ferrand, FranceUniversité Clermont Auvergne, Institut National de la santé et de la recherche en innovation (INSERM), Unité mixte de recherche (UMR) 1240 « Imagerie Moléculaire et Stratégies Théranostiques », Center Jean Perrin, Clermont-Ferrand, FranceDépartement d’Oncogénétique, Laboratoire d’Oncologie Moléculaire, Center Jean Perrin, Clermont-Ferrand, FranceIntroductionUveal melanoma (UM) is a rare ocular cancer. While germline mutations in genes such as BAP1 and MBD4 account for approximately 20% of familial UM cases, the hereditary factors underlying the remaining cases remain unknown. Epidemiological studies have suggested an increased risk of prostate cancer, thyroid cancer, and leukemia among patients with UM, indicating potential unidentified genetic predispositions. This study aims to identify new candidate genes associated with a hereditary predisposition to UM.MethodsThis single-center study, conducted at Centre Jean Perrin, will involve the exome sequencing of 50 patients with UM who do not harbor known pathogenic variants in the BAP1 or MBD4 genes. The primary objective is to identify novel candidate genes associated with hereditary cancer predisposition among UM patients. A several-step-bioinformatic analysis will be conducted to identify the genes of interest. A secondary objective is to explore genes known to be involved in predisposition to other cancers, already described in the occurrence of uveal melanoma, but where an association has not been fully established yet. The study has begun in October 2024, with patient recruitment lasting 12 months. No follow-up period is planned, but the duration of the genetic analyses is estimated at six months, with the final study report expected by October 2026.DiscussionThe identification of novel hereditary predisposition genes for UM could significantly enhance genetic counselling and surveillance strategies for families affected. This study could also contribute to a better understanding of the genetic landscape of UM, potentially leading to more personalized and effective options for its detection.Trial registrationClinicalTrials.gov, identifier NCT06550674, registered in August 2024. Protocol: version 1.0, January 18th, 2024.https://www.frontiersin.org/articles/10.3389/fonc.2025.1538924/fulluveal melanomagermline mutationsexome sequencinghereditary predispositionclinical trial |
| spellingShingle | Mélanie Godiveau Mélanie Godiveau Mélanie Godiveau Angeline Ginzac Angeline Ginzac Angeline Ginzac Yannick Bidet Yannick Bidet Flora Ponelle-Chachuat Flora Ponelle-Chachuat Maud Privat Maud Privat Xavier Durando Xavier Durando Xavier Durando Xavier Durando Mathias Cavaillé Mathias Cavaillé Mathis Lepage Mathis Lepage Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trial Frontiers in Oncology uveal melanoma germline mutations exome sequencing hereditary predisposition clinical trial |
| title | Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trial |
| title_full | Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trial |
| title_fullStr | Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trial |
| title_full_unstemmed | Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trial |
| title_short | Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trial |
| title_sort | identification of new candidate genes for the hereditary predisposition to uveal melanoma igcmu trial |
| topic | uveal melanoma germline mutations exome sequencing hereditary predisposition clinical trial |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1538924/full |
| work_keys_str_mv | AT melaniegodiveau identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT melaniegodiveau identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT melaniegodiveau identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT angelineginzac identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT angelineginzac identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT angelineginzac identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT yannickbidet identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT yannickbidet identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT floraponellechachuat identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT floraponellechachuat identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT maudprivat identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT maudprivat identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT xavierdurando identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT xavierdurando identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT xavierdurando identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT xavierdurando identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT mathiascavaille identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT mathiascavaille identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT mathislepage identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial AT mathislepage identificationofnewcandidategenesforthehereditarypredispositiontouvealmelanomaigcmutrial |